Figure 3. Activation of MAPK/ERK pathway is associated with the efficacy of Fc-enhanced anti-CTLA-4 therapy.
Kaplan-Meier survival curve of GL261-CV (IC, n = 9 and Fc-enhanced aCTLA-4, n = 10) and GL261-Mek1/2 p-Erkhigh (IC, n = 10 and Fc-enhanced aCTLA-4, n = 10) treated with IC or Fc-enhanced aCTLA-4 antibody. For treatment with ICB antibodies, treatment started 1 week after tumor implantation and delivered intravenously 4 times every 3 or 4 days. The P values were generated from low-rank test.